Galapagos N.V. (GLPG)

Galapagos NV (GLPG) Q4 2025 Earnings Call Transcript

Mechelen, Belgium; February 23, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today reported its financial results for the full year 2025 and provided an update on the fourth quarter 2025 and its year-to-date performance.

Mechelen, Belgium ; February 16, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Bank of America.

U.S. stock futures were mixed on Tuesday after a higher close on Monday.

U.S. stock futures up, focus on AngioDynamics, Microchip Tech, AAR earnings. Galapagos to wind down cell therapy.

Mechelen, Belgium ; January 5, 2026, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the works council consultation process regarding the wind-down of cell therapy activities has been completed and its Board of Directors has decided to initiate the wind-down of the Company's cell therapy activities.

Galapagos now presents a deep value opportunity, underpinned by a €3B cash reserve and a decisive shift to capital allocation discipline. GLPG's restructuring—discontinuing cell therapy, slashing headcount, and targeting cash flow neutrality by YE2026—positions it as a streamlined M&A platform. Management's M&A-focused pedigree, led by ex-AbbVie dealmakers, signals a pivot from pipeline reliance to transformative business development using its cash war chest.

High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time

Mechelen, Belgium ; November 26, 2025, 07:30 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America.

Galapagos NV ( GLPG ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Glenn Schulman Henry Gosebruch - CEO & Executive Director Aaron Cox - Chief Financial Officer Dan Grossman - Chief Strategy Officer Conference Call Participants Faisal Khurshid - Leerink Partners LLC, Research Division Brian Abrahams - RBC Capital Markets, Research Division Philip Nadeau - TD Cowen, Research Division Chi Meng Fong - BofA Securities, Research Division Jacob Mekhael - KBC Securities NV, Research Division Sebastiaan van der Schoot Delphine Le Louet - Sanford C. Bernstein & Co., LLC.

Oral presentation of GLPG5101 data from the ATALANTA-1 study in patients with high-risk relapsed/refractory mantle cell lymphoma

Mechelen, Belgium ; October 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new in vitro pharmacological data from its selective TYK2 inhibitor, GLPG3667, currently in two Phase 3-enabling studies in dermatomyositis (DM) and systemic lupus erythematosus (SLE), at the American College of Rheumatology (ACR) Convergence 2025, taking place in Chicago, IL, October 24-29, 2025.

Intention follows comprehensive strategic review process and would represent the optimal capital allocation pathway to support a stronger and sustainable future for Galapagos

Mechelen, Belgium; October 16, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointment of Mr. Fred Blakeslee as Executive Vice President and General Counsel effective October 16, 2025. Blakeslee is succeeding Ms. Valeria Cnossen, who will leave the Company after a short transition period.

Biotechnology firm Galapagos' board has received non-binding offers from consortia, mainly comprised of financial investors, for its cell-therapy business, the company said on Wednesday.

Mechelen, Belgium ; October 1, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and its Board of Directors today issued the following statement: